Limits...
Biomodification of PCL Scaffolds with Matrigel, HA, and SR1 Enhances De Novo Ectopic Bone Marrow Formation Induced by rhBMP-2.

Bao W, Gao M, Cheng Y, Lee HJ, Zhang Q, Hemingway S, Luo Z, Krol A, Yang G, An J - Biores Open Access (2015)

Bottom Line: In vivo investigations of de novo bone and bone marrow formation indicated that subcutaneous implantation of PCL scaffolds coated with recombinant human bone morphogenetic protein-2 (rhBMP-2) plus Matrigel, hydroxyapatite (HA), or StemRegenin 1 (SR1) improved formation of bone and hematopoietic bone marrow as determined by microcomputed tomography, and histological and hematopoietic characterizations.Our study provides evidence that thin PCL scaffolds biomodified with Matrigel, HA, and SR1 mimic the environments of real bone and bone marrow, thereby enhancing the de novo ectopic bone marrow formation induced by rhBMP-2.This ectopic bone marrow model will serve as a unique and essential tool for basic research and for clinical applications of postnatal tissue engineering and organ regeneration.

View Article: PubMed Central - PubMed

Affiliation: Department of Pharmacology, SUNY Upstate Medical University , Syracuse, New York. ; Cancer Research Institute, SUNY Upstate Medical University , Syracuse, New York. ; Department of Medicine, Liaoning University of Traditional Chinese Medicine , Shenyang, China .

ABSTRACT
The de novo formation of ectopic bone marrow was induced using 1.2-mm-thin polycaprolactone (PCL) scaffolds biomodified with several different biomaterials. In vivo investigations of de novo bone and bone marrow formation indicated that subcutaneous implantation of PCL scaffolds coated with recombinant human bone morphogenetic protein-2 (rhBMP-2) plus Matrigel, hydroxyapatite (HA), or StemRegenin 1 (SR1) improved formation of bone and hematopoietic bone marrow as determined by microcomputed tomography, and histological and hematopoietic characterizations. Our study provides evidence that thin PCL scaffolds biomodified with Matrigel, HA, and SR1 mimic the environments of real bone and bone marrow, thereby enhancing the de novo ectopic bone marrow formation induced by rhBMP-2. This ectopic bone marrow model will serve as a unique and essential tool for basic research and for clinical applications of postnatal tissue engineering and organ regeneration.

No MeSH data available.


Related in: MedlinePlus

Synergistic effects of rhBMP-2 and SR1 on the induction of alkaline phosphatase (ALP) activity in ATDC5 cells. ALP activity was significantly higher in ATDC5 cells treated with 10 ng rhBMP-2 and 0.25 μM SR than in cells treated with 0.25 μM SR1 alone or 10 ng rhBMP-2 alone (**p<0.01, n=3).
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4497713&req=5

f6: Synergistic effects of rhBMP-2 and SR1 on the induction of alkaline phosphatase (ALP) activity in ATDC5 cells. ALP activity was significantly higher in ATDC5 cells treated with 10 ng rhBMP-2 and 0.25 μM SR than in cells treated with 0.25 μM SR1 alone or 10 ng rhBMP-2 alone (**p<0.01, n=3).

Mentions: We also examined the possibility that rhBMP-2 and SR1 stimulate the osteogenic differentiation in ATDC5 cells. The presence of 0.25 μM SR1 significantly enhanced the ALP activity in ATDC5 cells induced by 10 ng rhBMP-2 (Fig. 6). The combination index (>1) between 0.25 μM SR1 and 10 ng rhBMP-2 indicated synergistic effects of rhBMP-2 and SR1 on ALP or osteogenic differentiation activity in these cells. These in vitro synergistic effects on osteogenic differentiation in ATDC5 cells were consistent with their notable in vivo synergistic effects on the de novo bone-inducing activity, that is, histological examination of the in vivo bone formation at 8 weeks after implantation revealed better bone- and bone marrow-inducing activity with PCL scaffolds coated with rhBMP-2 plus SR1 than with PCL scaffolds coated with either SR1 (data not shown) or rhBMP-2 (Figs. 2 and 4).


Biomodification of PCL Scaffolds with Matrigel, HA, and SR1 Enhances De Novo Ectopic Bone Marrow Formation Induced by rhBMP-2.

Bao W, Gao M, Cheng Y, Lee HJ, Zhang Q, Hemingway S, Luo Z, Krol A, Yang G, An J - Biores Open Access (2015)

Synergistic effects of rhBMP-2 and SR1 on the induction of alkaline phosphatase (ALP) activity in ATDC5 cells. ALP activity was significantly higher in ATDC5 cells treated with 10 ng rhBMP-2 and 0.25 μM SR than in cells treated with 0.25 μM SR1 alone or 10 ng rhBMP-2 alone (**p<0.01, n=3).
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4497713&req=5

f6: Synergistic effects of rhBMP-2 and SR1 on the induction of alkaline phosphatase (ALP) activity in ATDC5 cells. ALP activity was significantly higher in ATDC5 cells treated with 10 ng rhBMP-2 and 0.25 μM SR than in cells treated with 0.25 μM SR1 alone or 10 ng rhBMP-2 alone (**p<0.01, n=3).
Mentions: We also examined the possibility that rhBMP-2 and SR1 stimulate the osteogenic differentiation in ATDC5 cells. The presence of 0.25 μM SR1 significantly enhanced the ALP activity in ATDC5 cells induced by 10 ng rhBMP-2 (Fig. 6). The combination index (>1) between 0.25 μM SR1 and 10 ng rhBMP-2 indicated synergistic effects of rhBMP-2 and SR1 on ALP or osteogenic differentiation activity in these cells. These in vitro synergistic effects on osteogenic differentiation in ATDC5 cells were consistent with their notable in vivo synergistic effects on the de novo bone-inducing activity, that is, histological examination of the in vivo bone formation at 8 weeks after implantation revealed better bone- and bone marrow-inducing activity with PCL scaffolds coated with rhBMP-2 plus SR1 than with PCL scaffolds coated with either SR1 (data not shown) or rhBMP-2 (Figs. 2 and 4).

Bottom Line: In vivo investigations of de novo bone and bone marrow formation indicated that subcutaneous implantation of PCL scaffolds coated with recombinant human bone morphogenetic protein-2 (rhBMP-2) plus Matrigel, hydroxyapatite (HA), or StemRegenin 1 (SR1) improved formation of bone and hematopoietic bone marrow as determined by microcomputed tomography, and histological and hematopoietic characterizations.Our study provides evidence that thin PCL scaffolds biomodified with Matrigel, HA, and SR1 mimic the environments of real bone and bone marrow, thereby enhancing the de novo ectopic bone marrow formation induced by rhBMP-2.This ectopic bone marrow model will serve as a unique and essential tool for basic research and for clinical applications of postnatal tissue engineering and organ regeneration.

View Article: PubMed Central - PubMed

Affiliation: Department of Pharmacology, SUNY Upstate Medical University , Syracuse, New York. ; Cancer Research Institute, SUNY Upstate Medical University , Syracuse, New York. ; Department of Medicine, Liaoning University of Traditional Chinese Medicine , Shenyang, China .

ABSTRACT
The de novo formation of ectopic bone marrow was induced using 1.2-mm-thin polycaprolactone (PCL) scaffolds biomodified with several different biomaterials. In vivo investigations of de novo bone and bone marrow formation indicated that subcutaneous implantation of PCL scaffolds coated with recombinant human bone morphogenetic protein-2 (rhBMP-2) plus Matrigel, hydroxyapatite (HA), or StemRegenin 1 (SR1) improved formation of bone and hematopoietic bone marrow as determined by microcomputed tomography, and histological and hematopoietic characterizations. Our study provides evidence that thin PCL scaffolds biomodified with Matrigel, HA, and SR1 mimic the environments of real bone and bone marrow, thereby enhancing the de novo ectopic bone marrow formation induced by rhBMP-2. This ectopic bone marrow model will serve as a unique and essential tool for basic research and for clinical applications of postnatal tissue engineering and organ regeneration.

No MeSH data available.


Related in: MedlinePlus